John W. Shiver - 18 Jun 2026 Form 4 Insider Report for NOVAVAX INC (NVAX)

Reporting relationship: Director
Issuer ticker: NVAX
Reported as of: 18 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2026, 19:50:11 UTC
Prior SEC filing: 12 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark J. Casey, Attorney-in-Fact

Key filing fact

John W. Shiver filed Form 4 for NOVAVAX INC (NVAX) on 23 Jun 2026.

Key facts

This page summarizes John W. Shiver's Form 4 filing for NOVAVAX INC (NVAX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 23 Jun 2026, 19:50.

Change

Previous filing in this sequence was filed on 12 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001900372 Primary reporting owner

Shiver John W.

Relationship: Director
Address: 21 FIRSTFIELD ROAD, GAITHERSBURG
Signature: /s/ Mark J. Casey, Attorney-in-Fact
Signature date: 23 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NVAX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +21,270
Change %
Price: $0.000000^*
Shares after: 21,270
Date: 18 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 21,270
Exercise price: $9.13
Footnotes: F1

NVAX transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +14,180
Change %
Price: $0.000000^*
Shares after: 14,180
Date: 18 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,180
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.

Footnote F2

Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

Footnote F3

One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.